Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 5NIH 3NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Neuroblastoma 5Medulloblastoma 5Carcinoma 4Mouth Neoplasms 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Ganglioneuroblastoma 3Vulvar Neoplasms 2Stomach Neoplasms 2Oropharyngeal Neoplasms 2Gallbladder Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Vomiting 1Urinary Bladder Neoplasms 1Teratoma 1Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7 1Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 1Sertoli-Leydig Cell Tumor 1Rhabdoid Tumor 1Recurrent Uterine Corpus Carcinoma 1Papillomavirus Infections 1Ovarian gynandroblastoma 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Nausea 1Lymphoid Interstitial Pneumonia 1

Interventions

Gemcitabine 18Cisplatin 14Paclitaxel 9Vinblastine 7Methotrexate 7Radiotherapy 6Doxorubicin 6Carboplatin 6Fluorouracil 4Surgical Procedures, Operative 3Mitomycin 3Filgrastim 3BCG Vaccine 3Gefitinib 2Docetaxel 2Cystectomy 2valrubicin 1rubitecan 1romidepsin 1piritrexim 1merphos 1lonafarnib 1durvalumab 1avelumab 1atezolizumab 1Watchful Waiting 1Urination 1Transurethral Resection of Bladder 1Taxes 1Radiotherapy, Conformal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Urinary Bladder Neoplasms × Platinum × Clear all
NCT04871529 2024-12-30

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

SWOG Cancer Research Network

Phase 2 Terminated
6 enrolled 12 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡